Table 3.
Genotype | Treatment (weeks) | n | No. (%) of mice with disease | No. (%) of mice with CAH | Mice with invasion | No. of CAH per mouse (mean ± SD) | Size (mm2) of CAH (mean ± SD) | Range of size (mm2) |
---|---|---|---|---|---|---|---|---|
Pten+/−(E) | 24 | 5 | 5/5 (100) | 5 | 3 | 19.8 ± 3.86‡ | 0.20 ± 0.17 | 0.04–1.2 |
Pten+/−(P) | 24 | 5 | 5/5 (100) | 5 | 0 | 24.4 ± 9.29‡ | 0.14 ± 0.11 | 0.04–0.8 |
Wild type (E) | 24 | 5⁎ | 0 | 0 | 0 | |||
Pten+/−(E) | 12 | 7 | 7/7 (100)† | 6 | 0 | 6.86 ± 4.30§ | 0.11 ± 0.09 | 0.04–0.25 |
Pten+/−(P) | 12 | 7 | 7/7 (100) | 7 | 0 | 8.4 ± 5.27§ | 0.12 ± 0.09 | 0.04–0.4 |
Wild type (E) | 12 | 6⁎ | 0 | 0 | 0 |
E, estradiol pellets; P, placebo pellets.
Mice had dilated complex hyperplasia without atypia.
One mouse showed hyperplasia without atypia.
P > 0.05, difference was not statistically significant.
P > 0.05, difference was not statistically significant. These numbers were not compared with those in ‡.